US Stock MarketDetailed Quotes

INCY Incyte

Watchlist
  • 60.430
  • +0.910+1.53%
Close Apr 29 16:00 ET
  • 60.140
  • -0.290-0.48%
Pre 06:58 ET
11.70BMarket Cap302.15P/E (TTM)

About Incyte Company

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Company Profile

SymbolINCY
Company NameIncyte
Listing DateNov 4, 1993
Issue Price7.50
Founded1991
CEOMr. Herve Hoppenot
MarketNASDAQ
Employees2617
Fiscal Year Ends12-31
Address1801 Augustine Cut-Off
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19803
Phone1-302-498-6700
Websitehttp://www.incyte.com

Company Executives

  • Name
  • Position
  • Salary
  • Herve Hoppenot
  • Chairman of the Board, President and Chief Executive Officer
  • 16.66M
  • Christiana Stamoulis, M.B.A.
  • Executive Vice President and Chief Financial Officer
  • 5.08M
  • Thomas Tray
  • Vice President and Chief Accounting Officer
  • --
  • Dr. Steven H. Stein, M.D.
  • Executive Vice President and Chief Medical Officer
  • 5.63M
  • Barry P. Flannelly, Pharm.D.
  • Executive Vice President and General Manager, North America
  • 4.09M
  • Matteo Trotta
  • Executive Vice President and General Manager, Dermatology US
  • --
  • Sheila A Denton
  • Executive Vice President, General Counsel and Corporate Secretary
  • --
  • Paula J. Swain
  • Executive Vice President, Human Resources
  • --
  • Vijay K. Iyengar
  • Executive Vice President, Global Strategy and Corporate Development
  • --
  • Mohamed Khairie Issa
  • Executive Vice President and Head of US Oncology
  • --
  • Michael James Morrissey
  • Executive Vice President and Head of Global Technical Operations
  • --
  • Lee Heeson
  • Executive Vice President, Incyte International
  • --
  • Dr. Pablo J. Cagnoni, M.D.
  • President and Head of Research and Development
  • 15.83M
  • Paul J. Clancy
  • Independent Director
  • 479.76K
  • Julian C. Baker
  • Lead Independent Director
  • 512.76K
  • Jean-Jacques Bienaime
  • Independent Director
  • 478.76K
  • Dr. Susanne Schaffert, PhD
  • Independent Director
  • 444.76K
  • Dr. Otis W. Brawley,M.D.
  • Independent Director
  • 454.76K
  • Dr. Katherine A. High, M.D.
  • Independent Director
  • 454.76K
  • Dr. Jacqualyn A. Fouse, PhD
  • Independent Director
  • 466.26K
  • Dr. Edmund P. Harrigan, M.D.
  • Independent Director
  • 482.26K

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

No. Symbol Price
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
11.940
Collegium Pharmaceutical
COLL
27.600
Cars.com
CARS
12.100
4
Workday
WDAY
243.390
5
eBay
EBAY
67.200
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks Show More
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀

Monetary Policy: Navigating the Fed's Rate Cut Cycle

Changing Fed policy is altering the market math for investors.